202 related articles for article (PubMed ID: 31974203)
1. AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes.
Rab MAE; Van Oirschot BA; Kosinski PA; Hixon J; Johnson K; Chubukov V; Dang L; Pasterkamp G; Van Straaten S; Van Solinge WW; Van Beers EJ; Kung C; Van Wijk R
Haematologica; 2021 Jan; 106(1):238-249. PubMed ID: 31974203
[TBL] [Abstract][Full Text] [Related]
2. Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.
Zhuang-Yan A; Shirley M
Drugs; 2023 Nov; 83(17):1613-1620. PubMed ID: 37991635
[TBL] [Abstract][Full Text] [Related]
3. AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.
Kung C; Hixon J; Kosinski PA; Cianchetta G; Histen G; Chen Y; Hill C; Gross S; Si Y; Johnson K; DeLaBarre B; Luo Z; Gu Z; Yao G; Tang H; Fang C; Xu Y; Lv X; Biller S; Su SM; Yang H; Popovici-Muller J; Salituro F; Silverman L; Dang L
Blood; 2017 Sep; 130(11):1347-1356. PubMed ID: 28760888
[TBL] [Abstract][Full Text] [Related]
4. Residual pyruvate kinase activity in PKLR-deficient erythroid precursors of a patient suffering from severe haemolytic anaemia.
Klei TRL; Kheradmand Kia S; Veldthuis M; Beuger BM; Geissler J; Dehbozorgian J; Karimi M; van Bruggen R; van Zwieten R
Eur J Haematol; 2017 Jun; 98(6):584-589. PubMed ID: 28295642
[TBL] [Abstract][Full Text] [Related]
5. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
van Beers EJ; Al-Samkari H; Grace RF; Barcellini W; Glenthøj A; DiBacco M; Wind-Rotolo M; Xu R; Beynon V; Patel P; Porter JB; Kuo KHM
Blood Adv; 2024 May; 8(10):2433-2441. PubMed ID: 38330179
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
Grace RF; Rose C; Layton DM; Galactéros F; Barcellini W; Morton DH; van Beers EJ; Yaish H; Ravindranath Y; Kuo KHM; Sheth S; Kwiatkowski JL; Barbier AJ; Bodie S; Silver B; Hua L; Kung C; Hawkins P; Jouvin MH; Bowden C; Glader B
N Engl J Med; 2019 Sep; 381(10):933-944. PubMed ID: 31483964
[TBL] [Abstract][Full Text] [Related]
7. Targeting the red cell enzyme pyruvate kinase with a small allosteric molecule AG-348 may correct underlying pathology of a glycolytic enzymopathy.
Alayash AI
Haematologica; 2021 Jan; 106(1):9-11. PubMed ID: 33386714
[No Abstract] [Full Text] [Related]
8. Novel type of red blood cell pyruvate kinase hyperactivity predicts a remote regulatory locus involved in PKLR gene expression.
van Oirschot BA; Francois JJ; van Solinge WW; van Wesel AC; Rijksen G; van Amstel HK; van Wijk R
Am J Hematol; 2014 Apr; 89(4):380-4. PubMed ID: 24375447
[TBL] [Abstract][Full Text] [Related]
9. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Wills J; Horenstein M; Kim A; Silva MA; Dima L
Am J Ther; 2023 Sep-Oct 01; 30(5):e433-e438. PubMed ID: 37713687
[TBL] [Abstract][Full Text] [Related]
10. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.
Glenthøj A; van Beers EJ; Al-Samkari H; Viprakasit V; Kuo KHM; Galactéros F; Chonat S; Porter J; Zagadailov E; Xu R; Oluyadi A; Hawkins P; Gheuens S; Beynon V; Barcellini W;
Lancet Haematol; 2022 Oct; 9(10):e724-e732. PubMed ID: 35988546
[TBL] [Abstract][Full Text] [Related]
11. Partial pyruvate kinase deficiency aggravates the phenotypic expression of band 3 deficiency in a family with hereditary spherocytosis.
van Zwieten R; van Oirschot BA; Veldthuis M; Dobbe JG; Streekstra GJ; van Solinge WW; Schutgens RE; van Wijk R
Am J Hematol; 2015 Mar; 90(3):E35-9. PubMed ID: 25388786
[TBL] [Abstract][Full Text] [Related]
12. Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial.
Andrae DA; Grace RF; Jewett A; Foster B; Klaassen RJ; Salek S; Li J; Tai F; Boscoe AN; Zagadailov E
J Patient Rep Outcomes; 2023 Nov; 7(1):112. PubMed ID: 37943362
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
Yang H; Merica E; Chen Y; Cohen M; Goldwater R; Kosinski PA; Kung C; Yuan ZJ; Silverman L; Goldwasser M; Silver BA; Agresta S; Barbier AJ
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):246-259. PubMed ID: 30091852
[TBL] [Abstract][Full Text] [Related]
14. Mitapivat for sickle cell disease and thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
[TBL] [Abstract][Full Text] [Related]
15. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
[TBL] [Abstract][Full Text] [Related]
16. Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease.
Xu JZ; Vercellotti GM
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):107-113. PubMed ID: 38066891
[TBL] [Abstract][Full Text] [Related]
17. AMPD3-deficient mice exhibit increased erythrocyte ATP levels but anemia not improved due to PK deficiency.
Cheng J; Morisaki H; Toyama K; Ikawa M; Okabe M; Morisaki T
Genes Cells; 2012 Nov; 17(11):913-22. PubMed ID: 23078545
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Malaria Phenotypes by Pyruvate Kinase (PKLR) Variants in a Thai Population.
van Bruggen R; Gualtieri C; Iliescu A; Louicharoen Cheepsunthorn C; Mungkalasut P; Trape JF; Modiano D; Sirima BS; Singhasivanon P; Lathrop M; Sakuntabhai A; Bureau JF; Gros P
PLoS One; 2015; 10(12):e0144555. PubMed ID: 26658699
[TBL] [Abstract][Full Text] [Related]
19. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H; Galactéros F; Glenthøj A; Rothman JA; Andres O; Grace RF; Morado-Arias M; Layton DM; Onodera K; Verhovsek M; Barcellini W; Chonat S; Judge MP; Zagadailov E; Xu R; Hawkins P; Beynon V; Gheuens S; van Beers EJ;
N Engl J Med; 2022 Apr; 386(15):1432-1442. PubMed ID: 35417638
[TBL] [Abstract][Full Text] [Related]
20. Increased adsorption of cytoplasmic proteins to the erythrocyte membrane in ATP-depleted normal and pyruvate kinase-deficient mature cells and reticulocytes.
Allen DW; Groat JD; Finkel B; Rank BH; Wood PA; Eaton JW
Am J Hematol; 1983 Feb; 14(1):11-25. PubMed ID: 6837565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
